Down But Not Out, Ranbaxy Eyes Generics Blockbuster Launches In China
This article was originally published in PharmAsia News
Executive Summary
Fierce competition makes China a tough nut to crack for generics, something India’s largest drug manufacturer Ranbaxy says it has learned the hard way, but after walking away from a joint venture, the firm is ready to try again.
You may also be interested in...
Slow Growth And Tough Market Make China An Intriguing Puzzle For Indian Companies
MUMBAI - For large Indian drug companies, China has been a traditional and, to an extent, a dreaded rival in the business of pharmaceutical raw materials. Gargantuan Chinese factories that cropped up in the eighties almost killed scores of Indian bulk drug manufacturing units as every pricing strategy the Indian outfits could conceive of failed to beat the quotations offered by Chinese manufacturers to global brand name companies
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.